Kodiak Sciences Inc. ($kod) has been in focus as it prepares to release topline data from its pivotal DAYBREAK Phase 3 trial evaluating Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for wet age-related macular degeneration (wet AMD). The results, expected on September 28, 2026, at 8:30 AM ET, are highly anticipated since they compare Kodiak’s candidates against Regeneron's Eylea, targeting a significant $15 billion anti-VEGF market. Investors responded positively ahead of the release, with shares rising roughly 7% on Monday amid broader market pressures from rising bond yields and geopolitical tensions affecting energy prices.
Beyond DAYBREAK, Kodiak is advancing other late-stage programs, including the PEAK and PINNACLE Phase 3 studies for KSI-101 in macular edema secondary to inflammation, with data expected later this year and into 2027. The company is also enrolling patients in the ALTO Phase 3 trial for diabetic macular edema, underscoring its commitment to expanding its retinal disease portfolio. Despite a current Zacks Rank of #4 (Sell), Kodiak remains a biotech stock to watch this fall due to these critical clinical readouts that could reshape investor expectations and valuation.
As the market remains closed tonight, investors will be watching closely when U.S. markets reopen tomorrow at 9:30 AM ET for any immediate reaction to the DAYBREAK study results and Kodiak’s clinical progress.
Did you know?
Stocks with upcoming clinical trial results often experience increased volatility, as investors react swiftly to new data that can dramatically alter a biotech company’s future prospects.
Disclaimer
This content is for entertainment and discussion purposes only. It is based on publicly available headlines and social media commentary, which can be messy and ever-evolving. We are not financial advisors, and this is not investment advice. The publisher may hold positions in securities mentioned. We aim to keep things accurate—if you catch something off, please let us know.
Powered by - Trading Watch Premium
This data is 100% free and is made possible by our Monthly Supporters.
No Comments